Severe forms of COVID-19 or influenza can trigger the development of lung cancer years after recovery. This was reported on ...

Respiratory illnesses such as COVID-19 and influenza are usually thought of as short-term infections that cause fever, cough, ...

Over the last two years, research has improved the understanding and treatment of disease. Using tools such as gene editing, ...

In a new documentary, broadcaster Maxine Hughes gives an unfiltered account of what it’s like to experience cancer ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...

Immutep (IMMP) stock plummeted 80% after the company halted its Phase III NSCLC trial for futility, triggering analyst downgrades and massive selling.

Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Inside a mobile lab, Our Lady of the Lake Regional Medical Center is showcasing the robotic technology its surgeons and doctors are using to detect and treat lung cancer.

ASX healthcare sector falls for week ending March 13, 2026 as Immutep slumps 90% as abandons Phase III lung cancer trial.